Evogene grants Dan Michael Falk 2,500 stock options

The options vest quarterly from September 4, 2026, and are scheduled to be fully vested by September 4, 2027.

Rhea-AI Filing Summary

Evogene Ltd. reported that director Dan Michael Falk received a grant of 2,500 stock options on September 4, 2026, under the company's 2021 Share Incentive Plan. The options cover 2,500 ordinary shares and have an exercise price of $0.58 per share.

The options vest quarterly at 25% per quarter beginning September 4, 2026, and become fully vested by September 4, 2027. The report also lists four direct option holdings: 1,800 underlying shares at $10.51, expiring September 15, 2032; 1,800 at $6.03, expiring May 11, 2033; 1,800 at $7.16, expiring June 13, 2034; and 2,500 at $1.29, expiring August 18, 2035.

Insider Trade Summary

Grant/Award: 2,500 shares

Grant/Award 5 txns

Insider Falk Dan Michael

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1, F2, F3	2,500	$0.00	$0.00
holding	Stock Option (right to buy) F4	--	--	--
holding	Stock Option (right to buy) F4	--	--	--
holding	Stock Option (right to buy) F4	--	--	--
holding	Stock Option (right to buy) F4	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 10,400 contracts for 7,900 underlying shares (Direct)

Footnotes (4)

1. F1. The exercise price of the stock options to purchase Ordinary Shares of the Issuer (the "Options") is New Israeli Shekels ("NIS") 1.75 per share, which is equivalent to $0.58 per share based on the representative exchange rate of NIS 3.0050 per U.S. dollar published by the Bank of Israel on September 4, 2026, the grant date.
2. F2. The transaction reported in this row consists of the grant by the Issuer's board of directors to the Reporting Person of 2,500 Options under the Issuer's 2021 Share Incentive Plan.
3. F3. The Options vest and become exercisable on a quarterly basis (25% per quarter) commencing on the grant date of September 4, 2026, such that they will be fully vested by September 4, 2027, the one-year anniversary of the grant date.
4. F4. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.

Key Figures

Option grant: 2,500 stock options Exercise price: $0.58 per ordinary share Vesting rate: 25% per quarter +4 more

7 metrics

Option grant 2,500 stock options Granted September 4, 2026 under the 2021 Share Incentive Plan

Exercise price $0.58 per ordinary share Price for the granted options

Vesting rate 25% per quarter Beginning September 4, 2026; fully vested by September 4, 2027

Existing option position 1,800 underlying ordinary shares at $10.51 per share Direct option holding expiring September 15, 2032

Existing option position 1,800 underlying ordinary shares at $6.03 per share Direct option holding expiring May 11, 2033

Existing option position 1,800 underlying ordinary shares at $7.16 per share Direct option holding expiring June 13, 2034

Existing option position 2,500 underlying ordinary shares at $1.29 per share Direct option holding expiring August 18, 2035

Key Terms

2021 Share Incentive Plan, exercise price, vest

3 terms

2021 Share Incentive Plan financial

"grant ... under the Issuer's 2021 Share Incentive Plan"

exercise price financial

"The exercise price ... is ... $0.58 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest financial

"vest and become exercisable on a quarterly basis"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many options did EVGN director Dan Michael Falk receive?

Dan Michael Falk received 2,500 stock options under Evogene Ltd.'s 2021 Share Incentive Plan, covering 2,500 ordinary shares at an exercise price of $0.58 per share.

When do the EVGN options granted to Dan Michael Falk vest?

The options vest at 25% per quarter beginning September 4, 2026, and become fully vested by September 4, 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/30/2026 - 08:06 AM Accepted by SEC EDGAR 09/30/2026 - 08:05 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Falk Dan Michael

(Last) (First) (Middle)

10 HAALIYA HASHNIYA ST.

(Street)

HERZELIYA 4632012

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
Evogene Ltd. [ EVGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.58(1)	09/04/2026		A(2)		2,500		(3)	09/04/2036	Ordinary Shares	2,500	$0	2,500	D
Stock Option (right to buy)(4)	$10.51							09/15/2023	09/15/2032	Ordinary Shares	1,800		1,800	D
Stock Option (right to buy)(4)	$6.03							05/11/2024	05/11/2033	Ordinary Shares	1,800		1,800	D
Stock Option (right to buy)(4)	$7.16							06/13/2025	06/13/2034	Ordinary Shares	1,800		1,800	D
Stock Option (right to buy)(4)	$1.29							08/18/2026	08/18/2035	Ordinary Shares	2,500		2,500	D

Explanation of Responses:

1. The exercise price of the stock options to purchase Ordinary Shares of the Issuer (the "Options") is New Israeli Shekels ("NIS") 1.75 per share, which is equivalent to $0.58 per share based on the representative exchange rate of NIS 3.0050 per U.S. dollar published by the Bank of Israel on September 4, 2026, the grant date.

2. The transaction reported in this row consists of the grant by the Issuer's board of directors to the Reporting Person of 2,500 Options under the Issuer's 2021 Share Incentive Plan.

3. The Options vest and become exercisable on a quarterly basis (25% per quarter) commencing on the grant date of September 4, 2026, such that they will be fully vested by September 4, 2027, the one-year anniversary of the grant date.

4. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.

Remarks:

Exhibit 24.1 - Power of Attorney.

	/s/ Nitsan Deutsch, attorney-in-fact	09/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)